Latest Breaking News On - ஹெரான் சிகிச்சை - Page 8 : comparemela.com

Date Time Dana-Farber research supports FDA approval for immunotherapy combination in advanced kidney cancer Combination of nivolumab and cabozantinib found to significantly improve progression-free survival and reduced the risk of death versus sunitinib in previously untreated patients with advanced kidney cancer An immunotherapy agent combined with a tyrosine kinase inhibitor drug whose clinical testing as a first-line treatment in advanced kidney cancer was led by Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, has become a standard therapy. The combination of nivolumab (OPDIVO ®) and cabozantinib (CABOMETYX ®) was approved today by the U.S. Food and Drug Administration (FDA) as a first-line treatment for patients with advanced renal cell carcinoma (RCC). The approval is based on results from CheckMate -9ER, a phase 3 trial evaluating the combination compared to sunitinib, a single agent treatment.

Tonik choueiriNancy kohlbergTakeda pharmaceutical companyGenitourinary oncology at dana farber cancer instituteSanofi aventisRoche productsBristol myers squibbVirtual congressDrug administrationFoundation medicine incHarvard medical schoolLank centerOno pharmaceutical coAnalysis groupGenitourinary oncologyDana farber cancer institute